PMID- 26488730
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20220409
IS  - 1421-9875 (Electronic)
IS  - 0257-2753 (Linking)
VI  - 33
IP  - 6
DP  - 2015 Oct
TI  - Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: 
      A Single-Center Experience Second Analysis.
PG  - 728-34
LID - 10.1159/000439079 [doi]
AB  - OBJECTIVES: Sorafenib has become a standard therapy for advanced hepatocellular 
      carcinoma following the demonstration of significant increase in progression-free 
      survival as well as overall survival (OS) in the 2-phase III trials. We examined 
      efficacy and adverse events (AEs) in patients treated with sorafenib over a 
      6-year period since approval in Japan. METHODS: Two hundred and forty-one 
      patients treated with sorafenib at the Kinki University Hospital were 
      retrospectively analyzed clinically for the factors related to survival periods, 
      tumor response evaluated by the Response Evaluation Criteria In Cancer of the 
      Liver (RECICL) and AEs. RESULTS: OS was 14.3 months. According to the RECICL, the 
      objective response and disease control rates were 18.6% (43 of 241) and 61.1% 
      (137 of 241), respectively. AEs were seen in 77.3% (187 of 241), with Grade 3 or 
      higher in 23.6% (57 of 241). The most frequent AE was hand-foot skin reaction in 
      109 patients (45.0%), and 28 patients (11.8%) showed Grade 3 or higher. 
      Significant factors contributing to the OS were treatment duration (p = 0.0204), 
      up-to-7 criteria (p = 0.0400), increase of Child-Pugh score (p = 0.0008) and 
      tumor response determined by the RECICL (p = 0.0007). CONCLUSION: Based on the 
      analysis, using many cases at a single center, we concluded that continuation of 
      treatment with sorafenib for >/=90 days without decrease of liver function was 
      critical if tumor response was determined as stable disease or higher.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Arizumi, Tadaaki
AU  - Arizumi T
AD  - Department of Gastroenterology and Hepatology, Kinki University School of 
      Medicine, Osaka-Sayama, Osaka, Japan.
FAU - Ueshima, Kazuomi
AU  - Ueshima K
FAU - Iwanishi, Mina
AU  - Iwanishi M
FAU - Chishina, Hirokazu
AU  - Chishina H
FAU - Kono, Masashi
AU  - Kono M
FAU - Takita, Masahiro
AU  - Takita M
FAU - Kitai, Satoshi
AU  - Kitai S
FAU - Inoue, Tatsuo
AU  - Inoue T
FAU - Yada, Norihisa
AU  - Yada N
FAU - Hagiwara, Satoru
AU  - Hagiwara S
FAU - Ida, Hiroshi
AU  - Ida H
FAU - Minami, Yasunori
AU  - Minami Y
FAU - Sakurai, Toshiharu
AU  - Sakurai T
FAU - Nishida, Naoshi
AU  - Nishida N
FAU - Kitano, Masayuki
AU  - Kitano M
FAU - Kudo, Masatoshi
AU  - Kudo M
LA  - eng
PT  - Journal Article
DEP - 20151021
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
EIN - Dig Dis. 2017;35(6):625-626. PMID: 29040998
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Retrospective Studies
MH  - Sorafenib
EDAT- 2015/10/22 06:00
MHDA- 2016/07/28 06:00
CRDT- 2015/10/22 06:00
PHST- 2015/10/22 06:00 [entrez]
PHST- 2015/10/22 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - 000439079 [pii]
AID - 10.1159/000439079 [doi]
PST - ppublish
SO  - Dig Dis. 2015 Oct;33(6):728-34. doi: 10.1159/000439079. Epub 2015 Oct 21.